Lantheus (NASDAQ:LNTH) Stock Price Crosses Below 50-Day Moving Average - Time to Sell?

Key Points

• Lantheus shares fell below their 50-day moving average, trading near $100.12 versus the $100.48 average, while remaining above the 200-day average of $96.84.
• Analyst sentiment is cautious: the stock has a consensus “Hold” rating from 14 analysts and an average price target of $108.11, though several firms recently downgraded their ratings or lowered targets.
• Lantheus exceeded quarterly expectations, reporting $1.55 in EPS versus a $1.30 estimate and $388.18 million in revenue versus a $363.23 million forecast; institutional investors own 99.06% of the shares.

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) crossed below its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $100.48 and traded as low as $100.08. Lantheus shares last traded at $100.12, with a volume of 520,129 shares.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Leerink Partners set a $102.50 target price on Lantheus in a research note on Monday, August 3rd. CJS Securities lowered shares of Lantheus from a "market outperform" rating to a "market perform" rating in a research report on Tuesday, August 4th. Weiss Ratings upgraded shares of Lantheus from a "hold (c)" rating to a "hold (c+)" rating in a report on Friday, September 25th. Brookline Capital Markets downgraded shares of Lantheus from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 28th. Finally, Truist Financial downgraded shares of Lantheus from a "buy" rating to a "hold" rating and lowered their price objective for the company from $125.00 to $102.50 in a research report on Monday, August 3rd. Four research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $108.11.

Lantheus Stock Down 0.1%

The business has a 50 day simple moving average of $100.48 and a 200 day simple moving average of $96.84. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89. The stock has a market cap of $6.53 billion, a PE ratio of 24.18 and a beta of -0.06.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.30 by $0.25. The company had revenue of $388.18 million for the quarter, compared to analyst estimates of $363.23 million. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The business's revenue was up 2.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.57 EPS. On average, equities research analysts forecast that Lantheus Holdings, Inc. will post 4.54 EPS for the current fiscal year.

Institutional Trading of Lantheus

A number of institutional investors have recently added to or reduced their stakes in the business. Diversified Management Inc. bought a new stake in Lantheus in the third quarter worth approximately $375,000. GAMMA Investing LLC lifted its stake in shares of Lantheus by 3.3% in the 3rd quarter. GAMMA Investing LLC now owns 3,457 shares of the medical equipment provider's stock valued at $344,000 after purchasing an additional 109 shares during the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Lantheus by 122.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 555 shares of the medical equipment provider's stock valued at $55,000 after purchasing an additional 306 shares during the last quarter. Integrated Wealth Concepts LLC boosted its holdings in Lantheus by 6.7% in the second quarter. Integrated Wealth Concepts LLC now owns 18,709 shares of the medical equipment provider's stock worth $2,076,000 after purchasing an additional 1,170 shares in the last quarter. Finally, Baird Financial Group Inc. boosted its holdings in Lantheus by 25.8% in the second quarter. Baird Financial Group Inc. now owns 29,356 shares of the medical equipment provider's stock worth $3,257,000 after purchasing an additional 6,013 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

About Lantheus

Lantheus Holdings, Inc NASDAQ: LNTH is a healthcare company that develops, manufactures and commercializes diagnostic and therapeutic products, with a focus on medical imaging and radiopharmaceuticals. Its products are used by physicians and healthcare providers to help detect, characterize and monitor disease.

The company's portfolio includes PYLARIFY (piflufolastat F 18), a positron emission tomography imaging agent used to identify prostate-specific membrane antigen-positive lesions in men with prostate cancer, and DEFINITY, an ultrasound-enhancing agent used to improve cardiac ultrasound imaging.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.